Halobetasol Propionate 0.01% / Tazarotene 0.045% is Effectiv
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
The topical corticosteroid halobetasol propionate (HP) and the retinoid tazarotene (TAZ) are effective in psoriasis treatment. To mitigate adverse cutaneous reactions observed with monotherapy, a fixed-combination HP 0.01%/TAZ 0.045% lotion has been developed for the treatment of plaque psoriasis in adults. A Study was conducted to investigate the long-term safety, efficacy, and maintenance of response with HP/TAZ lotion.

This was a 1-year, multicenter, open-label study in 555 adults with psoriasis (Investigator’s Global Assessment [IGA] score of 3 ["moderate"] or 4 ["severe"] and body surface area [BSA] of 3?12% at baseline). HP/TAZ was administered once daily for 8 weeks and then intermittently as needed in 4-week intervals for up to 1 year based on achievement of treatment success (IGA score of 0 ["clear"] or 1 ["almost clear"]). Maximum continuous exposure was 24 weeks.

Of 550 participants with post-baseline safety data, 318 (57.8%) achieved treatment success during the study.
--Of those, 54.4% achieved treatment success within the first 8 weeks; retreatment was not required for more than 4 weeks in over half (55.3%), and 6.6% did not require any retreatment.
--Among participants enrolled for the full 52 weeks, 77.5% maintained BSA less than 5% on treatment.
--There were marked improvements in severity of itching, dryness, and burning/stinging over the study course.
--The most common treatment-related adverse events were application site reactions of dermatitis, pruritus, pain, and irritation.

In particular, fixed-combination HP/TAZ lotion provided maintained efficacy with a favorable tolerability and safety profile, supporting its use for the long-term treatment and management of moderate-to-severe plaque psoriasis.

Source: https://onlinelibrary.wiley.com/doi/abs/10.1111/jdv.17114?af=R